title: Exceptions or alternatives to labeling requirements for products held by the Strategic National Stockpile. Final rule.
abstract: The Food and Drug Administration (FDA) is adopting as a final rule, without change, the interim final rule that issued regulations permitting FDA Center Directors to grant exceptions or alternatives to certain regulatory labeling requirements applicable to human drugs, biological products, or medical devices that are or will be included in the Strategic National Stockpile (SNS). FDA is taking this action to complete the rulemaking initiated with the interim final rule.
mesh_terms: D001688:Biological Products; D003257:Consumer Product Safety / Q000331:legislation & jurisprudence*; D004189:Disaster Planning / Q000331:legislation & jurisprudence*; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D004864:Equipment and Supplies; D006801:Humans; D007880:Legislation, Drug; D058873:Pandemics / Q000517:prevention & control; D004364:Pharmaceutical Preparations; D011356:Product Labeling / Q000331:legislation & jurisprudence*; D011634:Public Health / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
chemical_list: D001688:Biological Products; D004364:Pharmaceutical Preparations